drugset / Trial / NCT00560820

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

NCT00560820

Phase 1 Completed 11 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the effect of deferasirox on renal hemodynamics by determining glomerular filtration rate (GFR), renal plasma flow (RPF) and filtration fraction (FF).

Timeline

Start
2007-09
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferasirox Unknown 30 mg/kg